News | December 31, 2023
Roche to buy LumiraDx’s technology platform for US$ 295 million
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Ecolab’s continued leadership position on renowned sustainability indices demonstrates the company’s record of advancing sustainable growth
Innovent will supply sintilimab for the collaborated clinical trial
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
NEIAFMR to be developed as the national hub for folk medicine
The product is expected to be launched in December 2023
Subscribe To Our Newsletter & Stay Updated
